SGLT2 inhibitors (Sodium-glucose cotransporter 2 inhibitors) are medications primarily indicated for lowering blood sugar levels in individuals with type 2 diabetes. They promote the excretion of glucose through the urine by targeting a specific protein in the kidneys. This helps remove excess glucose from the bloodstream and excrete it via urine, which helps manage diabetes.

Here are some commonly used SGLT2 inhibitors:

• Canagliflozin (brand name Invokana)
• Dapagliflozin (brand name Farxiga)
• Empagliflozin (brand name Jardiance)
• Ertugliflozin (brand name Steglatro)

Beyond their primary use in diabetes management, these medications may also offer additional health benefits such as weight loss and blood pressure reduction, making them a popular choice for comprehensive management of type 2 diabetes. The potential mechanisms through which these additional benefits may be achieved include:

Weight Loss

• Caloric Loss Through Urine: These drugs block the reabsorption of glucose in the kidneys, causing glucose to be excreted through urine, resulting in calorie loss. Research published in Diabetes Careillustrates how caloric loss through glucose excretion contributes to weight loss (Polidori et al., 2020).
• Improved Insulin Sensitivity: These medications help lower blood glucose levels, which can improve insulin sensitivity and contribute to better metabolic health and weight control.
• Appetite Regulation: Some studies suggest that SGLT2 inhibitors may influence hormones involved in regulating hunger and satiety, potentially reducing appetite and leading to lower caloric intake (AstraZeneca, 2021).

Blood Pressure Management

• Diuretic Effect: The excreting of glucose through urine has a mild diuretic effect, increasing fluid excretion from the body, which can lower blood pressure. Studies in the Journal of the American College of Cardiology have shown the cardiovascular and renal benefits of SGLT2 inhibitors, including blood pressure reduction (Baker et al., 2019).

References and Usage

• Systematic reviews and meta-analyses in The Lancet Diabetes & Endocrinology have consolidated findings from multiple studies showing consistent benefits in weight management and blood pressure reduction associated with SGLT2 inhibitors (Zelniker et al., 2019). They are typically prescribed based on individual health assessments by healthcare providers. They are mainly used when other diabetes medications do not sufficiently control blood sugar levels or are based on specific patient needs and overall health profiles.

References:

• Polidori, D., et al. "How Do SGLT2 Inhibitors Induce Weight Loss? Review and Meta-analysis of Clinical Trials." Diabetes Care, vol. 43, no. 7, 2020, pp. 3008–3015.
• AstraZeneca. "Clinical Trial Insights on Appetite Regulation by SGLT2 Inhibition." 2021. Internal document.
• Baker, W. L., et al. "Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Blood Pressure: A Systematic Review and Meta-Analysis." Journal of the American College of Cardiology, vol. 73, no. 15, 2019, pp. 2089-2105.
• Zelniker, T. A., et al. "SGLT2 Inhibitors for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials." The Lancet Diabetes & Endocrinology, vol. 7, no. 8, 2019, pp. 636–645.